serine has been researched along with ac 7700 in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 13 (54.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, Y; Hatanaka, T; Hori, K; Morinaga, Y; Nakagawa, R; Nihei, Y; Ohishi, K; Ohsumi, K; Okano, A; Saito, S; Sato, Y; Suga, Y; Tsuji, T; Tsuruo, T | 1 |
| Hori, K; Nihei, Y; Saito, S; Sato, Y; Suzuki, M | 1 |
| Hori, K; Kubota, K; Saito, S | 1 |
| Aramaki, M; Etoh, T; Kawano, K; Kitano, S; Ohno, T; Sasaki, A; Tahara, K | 1 |
| Ehara, S; Harada, K; Morinaga, Y; Nihei, Y; Suga, Y; Suzuki, M | 1 |
| Hori, K; Saito, S | 2 |
| Hori, K | 1 |
| Coleman, RL; Gershenson, DM; Han, LY; Jennings, N; Kamat, AA; Kim, TJ; Kundra, V; Landen, CN; Langley, R; Lin, YG; Lu, C; Merritt, WM; Ravoori, M; Sood, AK; Spannuth, WA | 1 |
| Furumoto, S; Hori, K; Kubota, K | 1 |
| Delmonte, A; Sessa, C | 1 |
| Cosgrove, D; Lassau, N; Leguerney, I; Peronneau, P; Roche, A | 1 |
| Cai, YC; Xian, LJ; Zou, Y | 1 |
| Lenihan, DJ; Subbiah, IM; Tsimberidou, AM | 1 |
| LoRusso, P; Mita, A; Mita, M; Spear, MA | 1 |
| Clémenson, C; Deutsch, E; Jouannot, E; Merino-Trigo, A; Rubin-Carrez, C | 1 |
| Bahleda, R; Braghetti, A; Cohen, P; Delmonte, A; Farace, F; Hospitel, M; Lassau, N; Lorusso, P; Sessa, C; Soria, JC; Tolcher, A; Veyrat-Follet, C | 1 |
| Azzariti, A; Gnoni, A; Numico, G; Paradiso, A; Porcelli, L; Quatrale, AE | 1 |
| Fujisaka, Y; Hayashi, H; Kiyota, H; Kurata, T; Kuroda, S; Murakami, H; Nakagawa, K; Ono, A; Onozawa, Y; Takahashi, T; Tanaka, K; Watanabe, J; Yamamoto, N | 1 |
| Dieras, V; Eskens, FA; Fontaine, H; Hospitel, M; Oprea, C; Tosi, D; Tresca, P; Van der Gaast, A; Van Doorn, L; Veyrat-Follet, C | 1 |
| Allard, A; Bennouna, J; Chadjaa, M; Gorbounova, V; Grossi, F; Kowalski, DM; Reck, M; Rey, A; von Pawel, J | 1 |
| Bahleda, R; Capri, G; Daglish, B; Del Conte, G; Gianni, L; Hospitel, M; Oprea, C; Sessa, C; Soria, JC; Varga, A | 1 |
| Babovic, N; Blay, JY; Bompas, E; Chawla, SP; Cohen, P; Cupissol, D; Demetri, GD; Franke, FA; Isambert, N; Italiano, A; Le-Guennec, S; López-Pousa, A; Pápai, Z; Penel, N; Saâda-Bouzid, E; Santoro, A; Staddon, AP; Tolcher, AW | 1 |
| Ecstein-Fraisse, E; Hida, T; Horiike, A; Horio, Y; Nishio, M; Satouchi, M; Sunaga, Y | 1 |
5 review(s) available for serine and ac 7700
| Article | Year |
|---|---|
Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700).
Topics: Animals; Antineoplastic Agents; Microcirculation; Neoplasms; Rats; Regional Blood Flow; Serine; Stilbenes | 2005 |
AVE8062: a new combretastatin derivative vascular disrupting agent.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Neovascularization, Pathologic; Serine; Stilbenes; Tubulin | 2009 |
[Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Diphosphates; Endothelial Cells; Humans; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Organophosphorus Compounds; Serine; Stilbenes; Tubulin Modulators; Xanthones | 2010 |
Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic.
Topics: Angiogenesis Inhibitors; Blood Vessels; Clinical Trials as Topic; Diketopiperazines; Humans; Neoplasms; Neovascularization, Pathologic; Serine; Tubulin | 2011 |
New vascular disrupting agents in upper gastrointestinal malignancies.
Topics: Angiogenesis Inhibitors; Animals; Bibenzyls; Diphosphates; Gastrointestinal Neoplasms; Humans; Neovascularization, Pathologic; Organophosphorus Compounds; Serine; Stilbenes; Upper Gastrointestinal Tract | 2014 |
7 trial(s) available for serine and ac 7700
| Article | Year |
|---|---|
Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.
Topics: Adult; Aged; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Serine; Treatment Outcome | 2013 |
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.
Topics: Asian People; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neovascularization, Pathologic; Serine | 2014 |
A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; Serine; Taxoids; Treatment Outcome; Young Adult | 2014 |
DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Serine; Taxoids; Treatment Outcome | 2014 |
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Serine; Taxoids; Young Adult | 2014 |
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Cisplatin; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ifosfamide; Male; Middle Aged; Proportional Hazards Models; Sarcoma; Serine; Treatment Outcome | 2015 |
Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Serine; Taxoids; Treatment Outcome | 2018 |
12 other study(ies) available for serine and ac 7700
| Article | Year |
|---|---|
A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Inbred ICR; Neoplasm Transplantation; Neoplasms, Experimental; Serine; Stilbenes; Survival Analysis; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1999 |
Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.
Topics: Animals; Antineoplastic Agents; Blood Pressure; Body Weight; Disease Models, Animal; Drug Screening Assays, Antitumor; Lymphatic Metastasis; Male; Neoplasm Transplantation; Neoplasms, Experimental; Rats; Regional Blood Flow; Serine; Stilbenes; Survival Rate | 1999 |
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Screening Assays, Antitumor; Heart Neoplasms; Kidney Neoplasms; Liver Neoplasms, Experimental; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Transplantation; Organ Specificity; Prodrugs; Rats; Regional Blood Flow; Sarcoma, Yoshida; Serine; Skin Window Technique; Stomach Neoplasms; Tumor Cells, Cultured; Vasoconstrictor Agents | 2002 |
Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Disease Models, Animal; Liver Neoplasms, Experimental; Male; Neoplasm Transplantation; Neovascularization, Pathologic; Rats; Serine; Survival Rate; Tubulin; Tumor Cells, Cultured | 2002 |
Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cisplatin; Colonic Neoplasms; Drug Administration Schedule; Humans; Lung Neoplasms; Mice; Mice, Inbred ICR; Mice, Nude; Sarcoma 180; Serine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis.
Topics: Animals; Arterioles; Blood Flow Velocity; Blood Pressure; Lung Neoplasms; Male; Microcirculation; Muscle, Smooth, Vascular; Neoplasm Transplantation; Rats; Sarcoma, Yoshida; Serine; Tumor Cells, Cultured; Vasoconstriction; Vasoconstrictor Agents | 2003 |
Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700).
Topics: Animals; Antineoplastic Agents, Phytogenic; Catecholamines; Epinephrine; Necrosis; Neoplasms, Experimental; Rats; Regional Blood Flow; Sarcoma; Serine; Soft Tissue Neoplasms; Stilbenes | 2004 |
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Female; Fluorodeoxyglucose F18; G2 Phase; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Serine; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth.
Topics: Animals; Cell Proliferation; Combined Modality Therapy; Hemodynamics; Male; Neoplasms, Experimental; Rats; Regional Blood Flow; Serine | 2008 |
Contrast ultrasonography: necessity of linear data processing for the quantification of tumor vascularization.
Topics: Angiogenesis Inhibitors; Animals; Blood Flow Velocity; Contrast Media; Female; Image Enhancement; Image Processing, Computer-Assisted; Linear Models; Melanoma, Experimental; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Phantoms, Imaging; Phospholipids; Regional Blood Flow; Serine; Sulfur Hexafluoride; Ultrasonography, Doppler; Videotape Recording | 2010 |
Cardiovascular toxicity profiles of vascular-disrupting agents.
Topics: Angiogenesis Inhibitors; Bibenzyls; Cardiovascular System; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Quinazolines; Serine; Xanthones | 2011 |
The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Drug Synergism; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Serine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |